Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies
Recruiting
- Conditions
- Lymphoma
- Interventions
- Device: early detection test
- Registration Number
- NCT05275036
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
ASCEND-LYM is a prospective, multi-center, observational study aimed at detecting early stage lymphoma and constrcuting prognostic model by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 493 participants including lymphoid malignancies and benign diseases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 493
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cancer Arm early detection test Participants with new diagnosis of lymphoid malignancies, from whom blood samples will be collected. Benign Arm early detection test Participants with new diagnosis of benign lymphoid diseases, from whom blood samples will be collected.
- Primary Outcome Measures
Name Time Method The sensitivity and specificity of early detection model for lymphoma based on cfDNA methylation or combined with other biomarkers. 12 months
- Secondary Outcome Measures
Name Time Method The sensitivity and specificity of the optimal model in lymphoma patients at different clinical stages. 12 months The sensitivity and specificity of the optimal model in different subtypes of lymphoma patients. 12 months The rate of high-risk patients found by prognostic model for lymphoma based on cfDNA methylation or combined with other biomarkers. 24 months
Trial Locations
- Locations (1)
SunYat-sen university cancer center
🇨🇳Guangzhou, China